This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Reports First Quarter 2013 Financial Results

As of March 31, 2013, Curis' cash, cash equivalents, marketable securities and investments totaled $54.2 million and there were approximately 80.2 million shares of common stock outstanding.

Recent Operational Highlights
  • The CHMP of the European Medicines Agency (EMA) issued a positive recommendation for the conditional marketing approval of Erivedge for the treatment of advanced basal cell carcinoma in Europe. The European Commission, which has the authority to approve medicines for use in the European Union, generally delivers its final decision within three months of the CHMP recommendation. Curis would earn a $6 million milestone payment from Genentech/Roche upon the conditional approval of Erivedge.
  • Curis appointed Kenneth Pienta, M.D. to its Board of Directors.
  • Curis appointed Ali Fattaey, Ph.D. as its President and Chief Operating Officer.
  • Curis treated the first patient in a Phase I clinical study of CUDC-907 in relapsed or refractory lymphoma or multiple myeloma cancer patients. To date Curis has received an aggregate of $1.1 million in funding under its agreement with The Leukemia and Lymphoma Society related to the continued development of CUDC-907.

Upcoming Activities

Curis expects to present at the following investor conferences through July 2013:
  • Needham & Co. 12th Annual Healthcare Conference, April 30 – May 1, 2013, in New York City
  • Deutsche Bank 38th Annual dbAccess Health Care Conference, May 29-30, 2013, in Boston, Massachusetts
  • Jefferies 2013 Global Healthcare Conference, June 3-6, 2013, in New York City
  • Wells Fargo Securities 2013 Health Care Conference, June 18-19, 2013, in Boston, Massachusetts
  • BMO Capital Markets Biotech Corporate Access Day, July 30, 2013, in Boston, Massachusetts

Conference Call Information

Daniel Passeri, Chief Executive Officer of Curis, will host a conference call today, April 30, 2013, at 9:00 a.m. ET, to discuss Curis' financial results for the quarter as well as provide a corporate update.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs